The association between cyclooxygenase-2 1195 G/A polymorphism and hepatocellular carcinoma: Evidence from a meta-analysis

Tumor Biology

Volumn 34, Issue 3, 2013, Pages 1479-1484

  Bu, Xianmin ^a   Zhao, Chenghai ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

COX 2; Hepatocellular carcinoma; Meta analysis; Single nucleotide polymorphism

Indexed keywords

ADENOSINE; CYCLOOXYGENASE 2; GUANOSINE;

ARTICLE; ASIAN; CANCER GENETICS; CANCER RISK; CAUCASIAN; CYCLOOXYGENASE 2 GENE; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC POLYMORPHISM; HUMAN; LIVER CELL CARCINOMA; PRIORITY JOURNAL;

EID: 84878710420     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0672-8     Document Type: Article

References (28)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118-27.
2. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012.
3. Zhang J, Xu F, Ouyang C. Joint effect of polymorphism in the N-acetyltransferase 2 gene and smoking on hepatocellular carcinoma. Tumour Biol. 2012;33:1059-63.
4. Dong LM, Potter JD, White E, Ulrich CM, Cardon LR, Peters U. Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA. 2008;299:2423-36.
5. Rouzer CA, Marnett LJ. Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes p450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem Rev. 2011;111:5899-921.
6. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004;56:387-437.
7. Pazhang Y, Ahmadian S, Javadifar N, Shafiezadeh M. COX-2 and survivin reduction may play a role in berberine-induced apoptosis in human ductal breast epithelial tumor cell line. Tumour Biol. 2012;33:207-14.
8. Zhang H, Xu Y, Zhang Z, Liu R, Ma B. Association between COX-2 rs2745557 polymorphism and prostate cancer risk: a systematic review and meta-analysis. BMC Immunol. 2012;13:14.
9. Santovito D, Mezzetti A, Cipollone F. Cyclooxygenase and prostaglandin synthases: Roles in plaque stability and instability in humans. Curr Opin Lipidol. 2009;20:402-8.
10. Chang WS, Yang MD, Tsai CW, Cheng LH, Jeng LB, Lo WC, et al. Association of cyclooxygenase 2 single-nucleotide polymorphisms and hepatocellular carcinoma in Taiwan. Chin J Physiol. 2012;55:1-7.
11. Fan XJ, Qiu XQ, Yu HP, Zeng XY. Association of COX-2 gene SNPs with the risk of hepatocellular carcinoma [article in Chinese]. Chin J Cancer Prev Treat. 2011;18:405-9.
12. Liu LF, Zhang JL, Lin JS. The relationship between cyclooxygenase-2 gene-1195 G/A genotype and risk of HBV-induced HCC: a case-control study in Han Chinese people [article in Chinese]. Chin J Gastroenterol Hepatol. 2010;19:333-5.
13. Xu DK, Zhang XM, Zhao P, Cai JC. Association between single nucleotide polymorphisms in promoter of COX-2 gene and hereditary susceptibility to hepatocellular carcinoma [article in Chinese]. Chin J Hepatobiliary Surg. 2008;14:840-3.
14. Akkiz H, Bayram S, Bekar A, Akgollu E, Ulger Y. Functional polymorphisms of cyclooxygenase-2 gene and risk for hepatocellular carcinoma. Mol Cell Biochem. 2011;347:201-8.
15. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Health Research Institute Web site, 2012.
16. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
19. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101-29.
20. Bhopal R. Glossary of terms relating to ethnicity and race: for reflection and debate. J Epidemiol Community Health. 2004;58:441-5.
21. Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316:469.
22. Egger M. Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34.
23. He JH, Li YM, Zhang QB, Ren ZJ, Li X, Zhou WC, et al. Cyclooxygenase-2 promoter polymorphism -899 G/C is associated with hepatitis B-related liver cancer in a Chinese population of Gansu province. Chin Med J (Engl). 2011;124:4193-7.
24. He J, Zhang Q, Ren Z, Li Y, Li X, Zhou W, et al. Cyclooxygenase-2-765 G/C polymorphisms and susceptibility to hepatitis B-related liver cancer in Han Chinese population. Mol Biol Rep. 2012;39:4163-8.
25. Giacalone A, Montalto G, Giannitrapani L, Balasus D, Terranova A, Cervello M, et al. Association between single nucleotide polymorphisms in the cyclooxygenase-2, tumor necrosis factor-alpha, and vascular endothelial growth factor-A genes, and susceptibility to hepatocellular carcinoma. OMICS. 2011;15:193-6.
26. Muller-Decker K. Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence. Cancer Metastasis Rev. 2011;30:343-61.
27. Miyashita M, Ito T, Sakaki M, Kajiwara A, Nozawa H, Hiroishi K, et al. Genetic polymorphism in cyclooxygenase-2 promoter affects hepatic inflammation and fibrosis in patients with chronic hepatitis C. J Viral Hepat. 2012;19:608-14.
28. Wang YX, Gao JX, Wang XY, Zhang L, Liu CM. Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells. Tumour Biol. 2012;33:957-66.